Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033547 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT06033547 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 56 participants.
The verdict
NCT06033547, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The primary purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (PK) profiles of two different cabotegravir formulations in healthy adult participants. The study will initially start with the assessment of Cabotegravir Formulation F. Once the clinical batch of Cabotegravir Formulation G is available, this formulation will be assessed.
Interventions
- DRUG Cabotegravir Formulation F
- DRUG Cabotegravir Formulation G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2025-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06033547
The ClinicalTrials.gov registry entry for NCT06033547 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabotegravir Formulation F is the first listed.
NCT06033547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06033547 about?
NCT06033547 is a clinical study titled "A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants". The primary purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (PK) profiles of two different cabotegravir formulations in healthy adult participants. The study will initially start with the assessment of Cabotegravir Formulation F. Once the clinical batch of Cabote...
What is the current status of trial NCT06033547?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2023-09-12. Estimated completion is 2025-07-25.
What interventions are being tested in trial NCT06033547?
The interventions under investigation include: Cabotegravir Formulation F (DRUG), Cabotegravir Formulation G (DRUG).
Who is sponsoring clinical trial NCT06033547?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.